Rebecca Gail Gaffney, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatomyositis | 5 | 2019 | 259 | 1.010 |
Why?
|
| Lupus Erythematosus, Cutaneous | 6 | 2019 | 75 | 0.880 |
Why?
|
| Latent Tuberculosis | 2 | 2021 | 223 | 0.660 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 427 | 0.500 |
Why?
|
| Antirheumatic Agents | 1 | 2018 | 1383 | 0.310 |
Why?
|
| Pemphigus | 2 | 2019 | 107 | 0.300 |
Why?
|
| Rheumatology | 3 | 2019 | 619 | 0.240 |
Why?
|
| Quality of Life | 4 | 2019 | 13476 | 0.220 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 2160 | 0.220 |
Why?
|
| Skin Diseases | 2 | 2022 | 1084 | 0.210 |
Why?
|
| Disease Progression | 1 | 2019 | 13640 | 0.190 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 15908 | 0.170 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 85 | 0.160 |
Why?
|
| Auditory Perceptual Disorders | 1 | 2019 | 36 | 0.160 |
Why?
|
| Antibodies, Antinuclear | 1 | 2019 | 340 | 0.150 |
Why?
|
| Olivary Nucleus | 1 | 2019 | 131 | 0.150 |
Why?
|
| Mycophenolic Acid | 1 | 2020 | 349 | 0.150 |
Why?
|
| Pemphigoid, Bullous | 1 | 2018 | 110 | 0.140 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2019 | 529 | 0.120 |
Why?
|
| Prednisone | 1 | 2018 | 1566 | 0.110 |
Why?
|
| Speech Perception | 1 | 2019 | 512 | 0.110 |
Why?
|
| Calcinosis | 1 | 2022 | 1480 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 1615 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 8045 | 0.100 |
Why?
|
| Cochlea | 1 | 2019 | 848 | 0.100 |
Why?
|
| Fatigue | 1 | 2018 | 1555 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 1805 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 2254 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 14762 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4215 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2019 | 8066 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 11061 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2021 | 54871 | 0.050 |
Why?
|
| Speech Reception Threshold Test | 1 | 2019 | 16 | 0.040 |
Why?
|
| Male | 8 | 2020 | 364142 | 0.040 |
Why?
|
| Perceptual Masking | 1 | 2019 | 90 | 0.040 |
Why?
|
| Efferent Pathways | 1 | 2019 | 164 | 0.040 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2019 | 139 | 0.040 |
Why?
|
| Female | 8 | 2020 | 396520 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 629 | 0.040 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2019 | 256 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 24295 | 0.040 |
Why?
|
| Humans | 13 | 2022 | 766766 | 0.040 |
Why?
|
| Noise | 1 | 2019 | 296 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1287 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2019 | 892 | 0.030 |
Why?
|
| Middle Aged | 5 | 2020 | 223257 | 0.030 |
Why?
|
| Adult | 5 | 2020 | 223307 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2022 | 81635 | 0.030 |
Why?
|
| Aged | 4 | 2020 | 171343 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2019 | 1253 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 12985 | 0.030 |
Why?
|
| Methotrexate | 1 | 2020 | 1719 | 0.030 |
Why?
|
| International Cooperation | 1 | 2019 | 1434 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1791 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2019 | 1574 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3430 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2021 | 3158 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1885 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2019 | 2764 | 0.020 |
Why?
|
| Dermatology | 1 | 2019 | 905 | 0.020 |
Why?
|
| Young Adult | 3 | 2020 | 59939 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6779 | 0.020 |
Why?
|
| Adolescent | 3 | 2020 | 88904 | 0.020 |
Why?
|
| Child | 3 | 2020 | 80668 | 0.020 |
Why?
|
| Skin | 1 | 2019 | 4499 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 59550 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2020 | 65273 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2018 | 22248 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 20144 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41710 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 42577 | 0.010 |
Why?
|